Clinical Trial Search

Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1 — 77.4; 63.5; 74.5; 85.7 percentage of participants

Primary: Dose-limiting Toxicity (DLT) Events - Part A — 0; 2; 0; 0 participants

Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055

Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1

Primary: The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale — -0.35; -0.11 Difference (scores on a scale)

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Short Term and Long Term — 1; 5; 5; 9 Participants

Primary: Change in Inflammatory Lesions With Daily Use of NAG Compared With Vehicle After 12-weeks of Use. — -27; -44 % change of inflammatory lesions count — p=<0.01

Primary: Physician's Wart Assessment — 1.52; 2.23 score on a scale

Primary: Trough FEV1 — 2.4173; 2.3774; 2.2191 Liters — p=<0.001

Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 — -15.85; -10.56; -14.28; -10.14 units on a scale — p=0.0005

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs

Primary: Change From Baseline to Week 8 in Mean Daily Average Pain Score as Assessed by Numerical Rating Scale (NRS) — -1.42; -1.36 Units on a scale — p=0.590

Primary: Percentage Change From Baseline in Serum TTR at Month 6 — -72.0 percentage change from baseline in TTR

Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants